CAR T
Published on April 03, 2025
Investigating the risk of T cell malignancy after CAR T-cell therapy
by Nature Medicine
Dulery R, Guiraud V, Choquet S, et al. T Cell Malignancies After CAR T Cell Therapy in the DESCAR-T Registry. Nature Medicine. 2025; (doi: 10.1038/s41591-024-03458-w).
Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low. The finding is based on an analysis of the country's DESCAR-T registry, which includes information on all patients with hematologic malignancies who have undergone CAR-T treatment there since July 2018. Investigators determined that after median follow-up of 17.7 and 6.3 months, respectively, none of the 162 patients with B cell acute lymphoblastic leukemia nor any of the 368 patients with multiple myeloma developed a T cell malignancy following CAR T infusion. A single case was identified among the remaining 2,536 patients in the sample, who all had B cell lymphoma. The primary cutaneous CD30-positive T cell lymphoproliferative disorder, diagnosed 3 years after the affected individual received tisagenlecleucel therapy, appears to be related to the integration of a CAR clone into the tumor suppressor gene PLAAT4. The one case among 3,066 patients suggests that secondary tumors can form after CAR T, but rarely do.
Read More
![]()